KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Treasury Shares (2021 - 2025)

Rigel Pharmaceuticals has reported Treasury Shares over the past 5 years, most recently at $607621.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 56.89% year-over-year to $607621.0; the TTM value through Dec 2025 reached $607621.0, up 56.89%, while the annual FY2025 figure was $607621.0, 56.89% up from the prior year.
  • Treasury Shares for Q4 2025 was $607621.0 at Rigel Pharmaceuticals, up from $569106.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $4.1 million in Q1 2024 and troughed at $185938.0 in Q4 2023.
  • A 5-year average of $1.1 million and a median of $607621.0 in 2025 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: surged 387.8% in 2022 and later crashed 86.05% in 2025.
  • Year by year, Treasury Shares stood at $226250.0 in 2021, then soared by 387.8% to $1.1 million in 2022, then tumbled by 83.15% to $185938.0 in 2023, then soared by 108.29% to $387282.0 in 2024, then surged by 56.89% to $607621.0 in 2025.
  • Business Quant data shows Treasury Shares for RIGL at $607621.0 in Q4 2025, $569106.0 in Q3 2025, and $565846.0 in Q2 2025.